← Back to Calendar
Indication
Small cell lung cancer (SCLC) — B7-H3 ADC
Key Notes
IDeate-Lung01 Phase 2 trial data expected for presentation at ASCO 2026. Ifinatamab deruxtecan (I-DXd) is a B7-H3–targeted ADC with significant activity in SCLC, where treatment options remain limited.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.